Literature DB >> 14756561

Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition.

Yan Luo1, Richard A Smith, Ran Guan, Xuesong Liu, Vered Klinghofer, Jianwei Shen, Charles Hutchins, Paul Richardson, Tom Holzman, Saul H Rosenberg, Vincent L Giranda.   

Abstract

We have designed peptide inhibitors that potently inhibit Akt both in vitro and inside cells. These peptide inhibitors are selective for Akt versus other closely related kinases. The peptides inhibit the in vitro phosphorylation of a biotinylated Bad peptide by Akt with potency up to 100 nM. We have shown that the binding between Akt1 and these peptide inhibitors requires MgATP. Mutating the two putative Akt phosphorylation sites to Ala (nonsubstrate) in these peptides increases the inhibitory potency while mutating the sites to aspartic acid (phosphorylation mimetic) reduces the potency. When delivered into cells, these peptide inhibitors can inhibit cellular Akt activity and cell growth. Thus, these Akt-specific peptide inhibitors provide prototypes for peptide mimetic drugs as well as very useful tools to dissect cellular functions of Akt.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14756561     DOI: 10.1021/bi034515p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

Review 1.  Peptide reporters of kinase activity in whole cell lysates.

Authors:  Ding Wu; Juliesta E Sylvester; Laurie L Parker; Guangchang Zhou; Stephen J Kron
Journal:  Biopolymers       Date:  2010       Impact factor: 2.505

2.  Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity.

Authors:  Tung O Chan; Jin Zhang; Ulrich Rodeck; John M Pascal; Roger S Armen; Maureen Spring; Calin D Dumitru; Valerie Myers; Xue Li; Joseph Y Cheung; Arthur M Feldman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-26       Impact factor: 11.205

3.  Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation.

Authors:  Thuy Nguyen; Robert A Coover; Jenson Verghese; Richard G Moran; Keith C Ellis
Journal:  ACS Med Chem Lett       Date:  2014-03-07       Impact factor: 4.345

Review 4.  Recent development of anticancer therapeutics targeting Akt.

Authors:  John K Morrow; Lei Du-Cuny; Lu Chen; Emmanuelle J Meuillet; Eugene A Mash; Garth Powis; Shuxing Zhang
Journal:  Recent Pat Anticancer Drug Discov       Date:  2011-01       Impact factor: 4.169

Review 5.  The critical role of Akt in cardiovascular function.

Authors:  Prasanna Abeyrathna; Yunchao Su
Journal:  Vascul Pharmacol       Date:  2015-05-27       Impact factor: 5.773

6.  The role of Akt activation in the response to chemotherapy in pancreatic cancer.

Authors:  Colin M Parsons; Diego Muilenburg; Tawnya L Bowles; Subbulakshmi Virudachalam; Richard J Bold
Journal:  Anticancer Res       Date:  2010-09       Impact factor: 2.480

7.  Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents.

Authors:  Katherine J Kayser-Bricker; Matthew P Glenn; Sang Hoon Lee; Said M Sebti; Jin Q Cheng; Andrew D Hamilton
Journal:  Bioorg Med Chem       Date:  2008-09-27       Impact factor: 3.641

Review 8.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

9.  Multiple roles and therapeutic implications of Akt signaling in cancer.

Authors:  Emiliano Calvo; Victoria Bolós; Enrique Grande
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

10.  Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt.

Authors:  Young B Kim; Chang Won Kang; Sujeewa Ranatunga; Hua Yang; Said M Sebti; Juan R Del Valle
Journal:  Bioorg Med Chem Lett       Date:  2014-08-28       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.